Sumitomo Mitsui Trust Group Inc. Purchases 2,066 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Sumitomo Mitsui Trust Group Inc. increased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 0.7% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 293,542 shares of the biopharmaceutical company’s stock after acquiring an additional 2,066 shares during the period. Sumitomo Mitsui Trust Group Inc.’s holdings in Alnylam Pharmaceuticals were worth $95,721,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in ALNY. Bessemer Group Inc. raised its stake in shares of Alnylam Pharmaceuticals by 176.9% in the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 69 shares during the last quarter. Crossmark Global Holdings Inc. bought a new stake in Alnylam Pharmaceuticals in the 1st quarter worth about $275,000. Strs Ohio bought a new position in Alnylam Pharmaceuticals during the 1st quarter valued at about $7,781,000. GAMMA Investing LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 14.3% during the 1st quarter. GAMMA Investing LLC now owns 616 shares of the biopharmaceutical company’s stock valued at $166,000 after acquiring an additional 77 shares during the last quarter. Finally, Brighton Jones LLC bought a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth approximately $243,000. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Dennis A. Ausiello sold 31,448 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $436.58, for a total transaction of $13,729,567.84. Following the transaction, the director owned 911 shares in the company, valued at approximately $397,724.38. The trade was a 97.18% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jeffrey V. Poulton sold 3,821 shares of the stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $1,727,283.05. Following the completion of the sale, the executive vice president owned 54,052 shares of the company’s stock, valued at $24,434,206.60. The trade was a 6.60% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 98,144 shares of company stock valued at $44,160,261. Insiders own 1.50% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on ALNY. Canaccord Genuity Group raised their target price on shares of Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Oppenheimer upgraded Alnylam Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $490.00 price target on the stock in a research note on Monday, August 4th. Evercore ISI lifted their price objective on Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the stock an “outperform” rating in a report on Thursday, September 11th. Morgan Stanley upped their price objective on Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the company an “equal weight” rating in a research report on Monday, October 6th. Finally, Needham & Company LLC raised their target price on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a “buy” rating in a research report on Thursday, July 31st. Twenty-three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $466.92.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $463.43 on Friday. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The stock has a 50-day simple moving average of $459.27 and a two-hundred day simple moving average of $360.97. The firm has a market capitalization of $60.75 billion, a PE ratio of -187.62 and a beta of 0.36. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.86. The firm had revenue of $773.69 million for the quarter, compared to analysts’ expectations of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The business’s quarterly revenue was up 17.3% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.